Ctca Clinical Research Inc

1. Boehringer Ingelheim Pharmaceuticals, Inc. $820,537 19 payments
2. Genentech, Inc. $665,378 70 payments
3. GlaxoSmithKline, LLC. $368,451 74 payments
4. Taiho Oncology, Inc. $357,977 34 payments
5. Ipsen Bioscience Inc $282,618 69 payments
6. MacroGenics, Inc. $178,448 14 payments
7. Merck Sharp & Dohme Corporation $81,802 39 payments
8. Pfizer Inc. $76,983 20 payments
9. AbbVie, Inc. $73,370 6 payments
10. Sanofi US Services Inc. $65,822 10 payments

1. Phase 2 HR+ breast cancer xentuzumab + everolimus $648,249 10 payments
2. Tumor Agnostic Precision Immuno Oncology and Somatic Targeting Rational for You Tapistry Phase II $526,941 37 payments
3. Tas-120 $264,604 16 payments
4. Phase 3 HR & breast cancer xentuzumab & everoli $172,288 9 payments
5. RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy $152,543 14 payments
6. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $150,705 45 payments
7. RESILIENT A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection ONIVYDE Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy $130,075 55 payments
8. A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy VS Trastuzumab Plus Chemotherapy in the Treatment of Patients With Her2 Metastatic Breast Cancer Who Have Received Prior Anti-Her2 Therapies and Require Systemic Treatment $123,618 4 payments
9. A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab $94,270 10 payments
10. A Phase I/II, Open-Label, Parallel-Group, Dose Escalation and Expansio $78,323 4 payments

1. Professional salary support $178,223 13 payments
2. Other $225 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.